# EDGAR Filing Document

**Accession Number:** 0001900304
**File Stem:** 0001654954-26-001516
**Filing Date:** 2026-2
**Character Count:** 6459
**Document Hash:** 117f6a28aa2b526a1feceeca67e9759d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-001516.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0001654954-26-001516

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260225

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Haleon plc
- **CENTRAL INDEX KEY:** 0001900304
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41411
- **FILM NUMBER:** 26674044

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING 5, FIRST FLOOR
- **STREET 2:** THE HEIGHTS
- **CITY:** WEYBRIDGE
- **STATE:** X0
- **ZIP:** KT13 0NY
- **BUSINESS PHONE:** 44 1932 822000

**MAIL ADDRESS:**
- **STREET 1:** BUILDING 5, FIRST FLOOR
- **STREET 2:** THE HEIGHTS
- **CITY:** WEYBRIDGE
- **STATE:** X0
- **ZIP:** KT13 0NY

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DRVW 2022 Ltd
- **DATE OF NAME CHANGE:** 20211217

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **FORM 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

 **For the month of February 2026**

 **Commission File Number: 001-41411**

 **Haleon plc**

(Translation of registrant's name into English)

 **Building 5, First Floor, The Heights,**

 **Weybridge, Surrey, KT13 0NY**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

 **EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | 25 February 2026 - "Haleon Preliminary 2025 Full Year Results" |
| [99.2](fy25releasevf.pdf) | 25 February 2026 - "[Haleon Preliminary 2025 Full Year Results](fy25releasevf.pdf)" |

---

99.1 ![](a2455u000.jpg)

 **Haleon plc: Preliminary 2025 Full Year Results**

 **25 February 2026:** Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its preliminary full year results statement for the year ended 31 December 2025 is available at <u>http://www.rns-pdf.londonstockexchange.com/rns/2433U_1-2026-2-24.pdf</u>.

The preliminary full year results statement will also be available on the Haleon website <u>www.haleon.com/investors</u>, and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at <u>https://data.fca.org.uk/#/nsm/nationalstoragemechanism</u>.

 **Dividend**

Reflecting the strength of FCF generation during the year, alongside strong organic operating profit growth, the Board is proposing a 2025 total dividend of 7.1p per ordinary share which represents a payout ratio of approximately 38% of 2025 adjusted earnings (2024: 37%). This includes a final dividend of 4.9p per ordinary share.

Subject to shareholder approval, the final dividend will be paid on 14 May 2026 to holders of ordinary shares and US American Depositary Shares (ADS) on the register as of 10 April 2026 (the record date). The ex-dividend date for ordinary shares will be 9 April 2026 and for US American Depositary Shares (ADS) 10 April 2026. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme (DRIP), the election deadline will be 24 April 2026. The DRIP is provided by Equiniti Financial Services Limited, more information is available at <u>www.shareview.co.uk/info/drip</u>.

Subject to market conditions and Board approval, Haleon expects to grow its ordinary dividend at least in line with adjusted earnings.

 **Presentation for analysts and shareholders**

A recorded results presentation by Brian McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial Officer, will be available shortly after 7:00am GMT (8:00 am CET) on 25 February 2026 and can be accessed at <u>www.haleon.com/investors</u>. This will be followed by a Q&A session at 8:45am GMT (9:45am CET).

For analysts and shareholders wishing to ask questions, please use the dial-in details below which will have a Q&A facility:

---

| | |
|:---|:---|
| UK: | +44 (0) 808 189 0158 |
| US: | +1 855 979 6654 |
| All other: | +44 (0) 203 936 2999 |
| Passcode: | 049869 |

---

An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at <u>www.haleon.com/investors</u><u>.</u>

This information contains regulated information as per 6.3.7R of the Disclosure and Transparency Rules of the Financial Conduct Authority.

 **Amanda Mellor** 

 **Company Secretary** 

 **Enquiries**

---

| | | | |
|:---|:---|:---|:---|
| **Investors** | **Investors** | **Media** | **Media** |
| Jo Russell | +44 7787 392441 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel  | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
| Email: investor-relations@haleon.com | Email: investor-relations@haleon.com | Email: corporate.media@haleon.com | Email: corporate.media@haleon.com |

---

 **About Haleon**

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as *Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren* - are built on trusted science, innovation and deep human understanding.

For more information please visit <u>www.haleon.com</u>.

 **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **HALEON PLC**<br> *(Registrant)* | **HALEON PLC**<br> *(Registrant)* |
| Date: February 25, 2026 | By: | /s/ Amanda Mellor | /s/ Amanda Mellor |
|  |  | Name: | Amanda Mellor |
|  |  | Title: | Company Secretary |

---

### Attached PDF Documents

**Attachment 1:** `fy25releasevf.pdf`

_No text found in this document._